Clinical Trials Logo

Metastatic Breast Cancer (MBC) clinical trials

View clinical trials related to Metastatic Breast Cancer (MBC).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02312622 Completed - Clinical trials for Tumors Metastatic to Brain

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01471847 Completed - Clinical trials for Metastatic Breast Cancer (MBC)

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Start date: February 2012
Phase: Phase 1
Study type: Interventional

This is a prospective, multi-center, open-label, phase Ib/ II study (two parts) with patients that have locally advanced or metastatic HER2+ breast cancer. The first part (phase Ib) will investigate the MTD/ RP2D of the combination therapy of BEZ235 BID and weekly trastuzumab using a Bayesian model. Once MTD/ RP2D is established the second part (phase II) will start. Phase II will evaluate the efficacy and the safety of weekly trastuzumab plus BEZ235 BID compared to capecitabine and lapatinib.

NCT ID: NCT00236899 Completed - Clinical trials for Metastatic Breast Cancer (MBC)

Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC

Start date: September 2005
Phase: Phase 3
Study type: Interventional

Multi-center, randomized Phase III study. 4 arms. 360 Patient to enroll. Purpose is evaluate time to progression disease (PD).